CU24690B1 - COMPUESTOS DE AMINOÁCIDOS ÚTILES COMO INHIBIDORES DE LA INTEGRINA AVß6 - Google Patents

COMPUESTOS DE AMINOÁCIDOS ÚTILES COMO INHIBIDORES DE LA INTEGRINA AVß6

Info

Publication number
CU24690B1
CU24690B1 CU2021000027A CU20210027A CU24690B1 CU 24690 B1 CU24690 B1 CU 24690B1 CU 2021000027 A CU2021000027 A CU 2021000027A CU 20210027 A CU20210027 A CU 20210027A CU 24690 B1 CU24690 B1 CU 24690B1
Authority
CU
Cuba
Prior art keywords
avß6
amino acids
integrin inhibitors
useful amino
sub
Prior art date
Application number
CU2021000027A
Other languages
English (en)
Other versions
CU20210027A7 (es
Inventor
Jacob Cha
Nicole Cooper
Timothy Hom
Katerina Leftheris
Jr David J Morgans
Manuel Munoz
Maureen Reilly
Yajun Zheng
Original Assignee
Pliant Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliant Therapeutics Inc filed Critical Pliant Therapeutics Inc
Publication of CU20210027A7 publication Critical patent/CU20210027A7/es
Publication of CU24690B1 publication Critical patent/CU24690B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

<p>La invención se refiere a un compuesto de la fórmula (I)</p> <p>Espacio para la fórmula.</p> <p>como inhibidores de una o ambas de la integrina α<sub>v</sub>β1 y la integrina α<sub>v</sub>β6 que son útiles para tratar la fibrosis, tal como en esteatohepatitis no alcohólica (NASH), fibrosis pulmonar idiopática (IPF) y neumonía intersticial inespecífica (NSIP).</p>
CU2021000027A 2018-10-08 2019-10-08 COMPUESTOS DE AMINOÁCIDOS ÚTILES COMO INHIBIDORES DE LA INTEGRINA AVß6 CU24690B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862742901P 2018-10-08 2018-10-08
PCT/US2019/055252 WO2020076862A1 (en) 2018-10-08 2019-10-08 Amino acid compounds and methods of use

Publications (2)

Publication Number Publication Date
CU20210027A7 CU20210027A7 (es) 2021-11-04
CU24690B1 true CU24690B1 (es) 2023-12-07

Family

ID=70051340

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000027A CU24690B1 (es) 2018-10-08 2019-10-08 COMPUESTOS DE AMINOÁCIDOS ÚTILES COMO INHIBIDORES DE LA INTEGRINA AVß6

Country Status (23)

Country Link
US (2) US11180494B2 (es)
EP (1) EP3863711A4 (es)
JP (1) JP2022508657A (es)
KR (1) KR20210101205A (es)
CN (1) CN113195053A (es)
AU (1) AU2019358041A1 (es)
BR (1) BR112021006620A2 (es)
CA (1) CA3115643A1 (es)
CL (2) CL2021000863A1 (es)
CO (1) CO2021004279A2 (es)
CR (1) CR20210224A (es)
CU (1) CU24690B1 (es)
DO (1) DOP2021000054A (es)
EA (1) EA202190967A1 (es)
EC (1) ECSP21032717A (es)
IL (1) IL282026A (es)
JO (1) JOP20210056A1 (es)
MX (1) MX2021004015A (es)
PE (1) PE20211463A1 (es)
PH (1) PH12021550784A1 (es)
SG (1) SG11202103283RA (es)
TW (1) TW202028179A (es)
WO (1) WO2020076862A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201823208A (zh) 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
EA202190134A1 (ru) 2018-06-27 2021-03-26 Плайэнт Терапьютикс, Инк. Соединения аминокислот с неразветвленными линкерами и способы их применения
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CA3136745A1 (en) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
GB202010626D0 (en) * 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
US20120289481A1 (en) * 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
WO2016153054A1 (ja) 2015-03-25 2016-09-29 富士フイルム株式会社 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体
WO2018009501A1 (en) 2016-07-05 2018-01-11 The Rockefeller University Tetrahydronaphthyridinepentanamide integrin antagonists
TW201823208A (zh) 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
EP3538526B1 (en) 2016-11-08 2024-04-10 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
US11046685B2 (en) * 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
US20180244648A1 (en) 2017-02-28 2018-08-30 Lazuli, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2019173653A1 (en) 2018-03-07 2019-09-12 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI741268B (zh) 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
EA202190134A1 (ru) 2018-06-27 2021-03-26 Плайэнт Терапьютикс, Инк. Соединения аминокислот с неразветвленными линкерами и способы их применения
CR20210109A (es) 2018-08-29 2021-06-24 Morphic Therapeutic Inc INHIBICIÓN DE LA INTEGRINA av ß6
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
EP3843728A4 (en) 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
CA3136745A1 (en) 2019-04-08 2020-10-15 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds
EP4146264A1 (en) 2020-05-07 2023-03-15 Pliant Therapeutics, Inc. Treatment of respiratory diseases with amino acid compounds

Also Published As

Publication number Publication date
WO2020076862A1 (en) 2020-04-16
ECSP21032717A (es) 2021-06-30
EP3863711A1 (en) 2021-08-18
TW202028179A (zh) 2020-08-01
US11952376B2 (en) 2024-04-09
SG11202103283RA (en) 2021-04-29
AU2019358041A1 (en) 2021-05-20
JP2022508657A (ja) 2022-01-19
CO2021004279A2 (es) 2021-04-30
PE20211463A1 (es) 2021-08-05
CR20210224A (es) 2021-06-08
MX2021004015A (es) 2021-06-23
CN113195053A (zh) 2021-07-30
CA3115643A1 (en) 2020-04-16
EA202190967A1 (ru) 2021-09-17
US20200109141A1 (en) 2020-04-09
CU20210027A7 (es) 2021-11-04
US20220144829A1 (en) 2022-05-12
CL2021000863A1 (es) 2021-09-10
PH12021550784A1 (en) 2021-10-25
JOP20210056A1 (ar) 2021-03-24
DOP2021000054A (es) 2021-08-31
US11180494B2 (en) 2021-11-23
KR20210101205A (ko) 2021-08-18
BR112021006620A2 (pt) 2021-07-06
IL282026A (en) 2021-05-31
CL2023001331A1 (es) 2023-10-20
EP3863711A4 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CU24690B1 (es) COMPUESTOS DE AMINOÁCIDOS ÚTILES COMO INHIBIDORES DE LA INTEGRINA AVß6
CU24693B1 (es) Compuestos de aminoácido con enlazadores no ramificados como inhibidores de la integrina
CR20200452A (es) Compuestos de aminoacidos y métodos de uso
EA201790595A1 (ru) Пиримидиноны в качестве ингибиторов фактора xia
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
BR112014012288A2 (pt) métodos para diagnosticar e tratar fibrose pulmonar idiopática
EA201691421A1 (ru) Гетероарилы и их применение
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PH12016500895A1 (en) Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
EA201792161A1 (ru) Ингибиторы калликреинов плазмы и их применение для профилактики приступа наследственного ангионевротического отека
PH12018501575A1 (en) Indolinones compounds and their use in the treatment of fibrotic diseases
IN2013MU02905A (es)
IL291413A (en) 2-isoindole-4,3,1-oxadiazole derivatives useful as hdac6 inhibitors
MX2021000051A (es) Inhibidores de triazol glicolato oxidasa.
EA202092110A1 (ru) Аминокислотные соединения и способы применения